Zimlovisertib and Tofacitinib Combo Shows Promise in RA
TOPLINE: Zimlovisertib plus tofacitinib showed greater efficacy than tofacitinib alone in reducing Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) in patients with rheumatoid arthritis (RA), with a significant reduction observed at week 12. METHODOLOGY: This randomized, phase 2 study, conducted across 77 centers in 10 countries, aimed to evaluate the efficacy, safety, … Read more